Welcome to our dedicated page for Inspiremd news (Ticker: NSPR), a resource for investors and traders seeking the latest updates and insights on Inspiremd stock.
InspireMD, Inc. (NSPR) is a medical device company whose news flow centers on its CGuard® Prime carotid stent system and proprietary MicroNet™ mesh technology for stroke prevention. Company press releases and SEC filings describe InspireMD as the developer of CGuard® Prime for the treatment of carotid artery stenosis, with a focus on making its products a standard approach in carotid stenting.
News about InspireMD often covers clinical milestones and peer-reviewed publications. For example, the company announced that results from its C-GUARDIANS pivotal trial of the CGuard® Prime carotid stent system were published in the Journal of the American College of Cardiology, with data showing low rates of disabling stroke or myocardial infarction through 30 days and low ipsilateral stroke rates through one year. InspireMD has also highlighted external clinical evidence such as the CREST-2 study in the New England Journal of Medicine, which it views as supportive of carotid artery stenting combined with medical therapy.
Investors following NSPR can also expect updates on regulatory and commercial developments. Recent filings report FDA PMA approval for the CGuard Prime Carotid Stent System in the United States and subsequent announcements of a U.S. commercial launch. Quarterly earnings releases describe the impact of CGuard Prime on revenue and provide commentary on procedure volumes and expansion of the company’s commercial team.
Additional news items include capital-raising transactions, such as private placements and warrant exercises, as well as changes in board composition and senior medical leadership. Together, these updates give readers insight into InspireMD’s clinical progress, regulatory status, commercialization efforts, and corporate governance. This page aggregates such NSPR news so readers can review the company’s key announcements in one place.
InspireMD will showcase its CGuard™ Embolic Prevention System (EPS) at the upcoming LINC 2022 conference in Leipzig, Germany, from June 6-9. The live case transmission aims to exhibit the system's ease-of-use and patient safety features. CEO Marvin Slosman highlighted the significance of the event for engaging with the clinical community. Presentations will feature evidence supporting the superiority of CGuard™ EPS over conventional stents. The conference serves as a vital platform for discussing advancements in vascular medicine.
InspireMD reported a 20% increase in CGuard™ revenue, totaling $1,161,000 for Q1 2022. The company completed its first European enrollment in the C-Guardian FDA trial and established a logistics hub with BOMI Group to enhance market access. Despite operating expenses rising by 34.7% to $4,608,000, total revenue grew by 17.6%. However, the net loss increased to $4,481,000, or $0.57 per share. The CEO emphasized ongoing efforts in expanding market share and improving clinical outcomes.
InspireMD (Nasdaq: NSPR) will announce its first quarter 2022 financial results on May 10, 2022, before market opening. A conference call is scheduled for 8:30 a.m. ET the same day to review these results and discuss corporate developments. The call will be accessible via a webcast. InspireMD aims to utilize its MicroNet® technology for improving the outcomes in carotid stenting.
InspireMD, Inc. (Nasdaq: NSPR) has announced a Key Opinion Leader (KOL) webinar on its CGuard™ Embolic Prevention Stent System for treating Carotid Artery Disease and stroke prevention.
The webinar is scheduled for March 22, 2022, at 2 p.m. ET, featuring experts including Chris Metzger, Adnan Siddiqui, and Sean Lyden. They will discuss the unmet needs in the carotid/neurovascular market and how InspireMD's products could fill this gap.
The management team will share insights about leveraging their MicroNet technology to enhance stroke prevention and patient outcomes.
InspireMD reported strong revenue growth driven by its CGuard™ EPS, achieving an 87.5% increase in Q4 2021 over Q4 2020, totaling $1,291,000, and a 55.9% year-over-year growth for the full year with $4,495,000. The company established reimbursement approval for CGuard from the French National Authority and its inclusion in a major clinical trial. However, it reported a net loss of $4,097,000 for Q4 2021, widening from the previous year's loss. Despite expenses rising 27% due to clinical trials and expansion efforts, cash reserves stood strong at $34.0 million.
InspireMD, Inc. (NSPR) announced that its CGuard™ Carotid Stent has been approved for use in the CREST-2 Trial, a pivotal study sponsored by NINDS to assess treatment efficacy for carotid artery disease. This trial will involve approximately 2,480 participants over four years, focusing on preventing strokes in asymptomatic patients with significant carotid stenosis. CGuard, utilizing advanced MicroNet technology, enhances the stenting procedure. This inclusion in a major clinical trial marks a significant milestone, potentially validating InspireMD's technology and expanding market opportunities.
InspireMD, Inc. (NSPR) has announced it will report fourth quarter and full year 2021 financial results on March 8, 2022, prior to market opening. A conference call is scheduled for the same day at 8:30 a.m. ET to review these results and provide updates on corporate developments. The company focuses on its CGuard™ Embolic Prevention Stent System for carotid artery disease and stroke prevention. InspireMD aims to set industry standards with its proprietary MicroNet® technology, enhancing both acute and long-term patient outcomes.
InspireMD has appointed Dr. Adnan Siddiqui to its Scientific Advisory Board, enhancing its expertise in the management of vascular diseases. A neurovascular surgeon with extensive experience, Dr. Siddiqui's role aims to advance the CGuard™ Embolic Prevention Stent System and support the development of new indications. InspireMD emphasizes the CGuard's superior patient outcomes compared to traditional methods, emphasizing the potential for improved stroke prevention. The company aims to establish its MicroNet® technology as the standard in carotid stenting.
InspireMD, Inc. (Nasdaq: NSPR) will participate in the 16th Biennial Scientific Meeting of the International Andreas Gruentzig Society (IAGS) from January 31 - February 3, 2022, in Punta Cana, Dominican Republic. CEO Marvin Slosman is set to present on February 1 at 11:30 am EST. The meeting aims to tackle challenges in cardiovascular disease treatment and enhance collaboration among researchers and clinicians. InspireMD focuses on stroke prevention technology, particularly its CGuard™ Embolic Prevention Stent System.
InspireMD, Inc. (Nasdaq: NSPR) announced a live case demonstration of its CGuard™ Embolic Prevention Stent System at the ISET 2022 Conference on January 18, 2022. The presentation, led by Dr. Chris Metzger, aims to showcase the advantages of CGuard in preventing strokes caused by Carotid Artery Disease. With 40 patient enrollments in the C-Guardians IDE trial, the company received global recognition for CGuard’s safety and efficacy. InspireMD continues to strive to establish its technology as the industry standard for carotid stenting.